Table 3. Multivariate logistic regression analysis of inflammatory index.
| NLR | PLR | LMR | AGR | |||||
|---|---|---|---|---|---|---|---|---|
| OR (95%) | p | OR (95%) | p | OR (95%) | p | OR (95%) | p | |
| Age (years) | 0.011* | 0.004* | 0.106 | 0.419 | ||||
| ≤ 60 | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| > 60 | 11.246 (1.170–108.126) | 10.467 (1.943–56.379) | 4.546 (0.059–1.342) | 0.548 (0.124–2.411) | ||||
| Gender | 0.024* | 0.330 | 0.272 | 0.679 | ||||
| Male | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| Female | 0.373 (0.156–0.896) | .617 (0.231–1.644) | 1.717 (0.648–4.546) | 1.189 (0.524–2.700) | ||||
| Treatment history | 0.379 | 0.585 | 0.023* | 0.143 | ||||
| Primary | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| Recurrent | 1.599 (0.558–4.581) | 1.371 (0.443–4.243) | 0.288 (0.096–0.862) | 0.725 (0.265–1.982) | ||||
| Duration of symptoms | 0.218 | 0.052 | 0.579 | 0.074 | ||||
| ≤ 12 | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| > 12 | 2.022 (0.651–6.282) | 3.689 (0.928–14.657) | 0.700 (0.197–2.485) | 0.384 (0.132–1.116) | ||||
| Preoperative Frankel score | 0.873 | 0.596 | 0.315 | 0.795 | ||||
| A–C | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| D–E | 0.929 (0.375–2.298) | 0.760 (0.275–2.100) | 1.637 (0.625–4.290) | 0.891 (0.375–2.120) | ||||
| Tumor location | 0.888 | 0.380 | 0.611 | 0.415 | ||||
| Cervical | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| Thoracic | 0.625 (0.102–3.832) | 5.058 (0.568–45.084) | 0.989 (0.120–8.162) | 0.514 (0.093–2.843) | ||||
| Lumbar | 0.631 (0.156–2.556) | 1.313 (0.255–6.771) | 1.797 (0.358–9.031) | 1.507 (0.404–5.626) | ||||
| Sacrum | 0.942 (0.194–4.580) | 1.466 (0.242–8.881) | 2.400 (0.406–14.185) | 0.734 (0.159–3.385) | ||||
| Involved segment | 0.770 | 0.856 | 0.130 | 0.810 | ||||
| Monosegment | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| Multisegment | 1.166 (0.417–3.256) | 1.115 (0.346–3.595) | 0.416 (0.132–1.314) | 1.126 (0.429–2.953) | ||||
| Tumor length (cm) | 0.042* | 0.073 | 0.146 | 0.143 | ||||
| ≤ 3 | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| > 3 | 2.798 (1.039–7.539) | 2.447 (0.922–6.493) | 0.475 (0.174–1.295) | 0.506 (0.200–1.278) | ||||
| Preoperative embolization | 0.772 | 0.771 | 0.505 | 0.424 | ||||
| Yes | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| No | 1.159 (0.428–3.141) | 1.176 (0.395–3.496) | 1.452 (0.482–4.374) | 0.676 (0.258–1.770) | ||||
| Enneking staging | 0.420 | 0.127 | 0.451 | 0.182 | ||||
| I | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| II | 0.534 (0.103–2.757) | 8.037 (0.901–71.705) | 0.312 (0.046–2.137) | 0.273 (0.055–1.351) | ||||
| III | 0.425 (0.116–1.562) | 1.776 (0.454–6.947) | 0.514 (0.131–2.015) | 0.946 (0.285–3.144) | ||||
| Bisphosphonate treatment | 0.153 | 0.029* | 0.003* | 0.068 | ||||
| Yes | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| No | 1.905 (0.783–4.634) | 2.949 (1.098–7.917) | 0.234 (0.086–0.640) | 0.449 (0.188–1.072) | ||||
| Adjuvant radiotherapy | 0.827 | 0.386 | 0.573 | 0.843 | ||||
| Yes | 1.000 | 1.000 | 1.000 | 1.000 | ||||
| No | 1.104 (0.455–2.678) | 1.565 (0.566–4.322) | 1.334 (0.490–3.630) | 0.919 (0.397–2.128) | ||||
NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; LMR: lymphocyte-to-monocyte ratio: AGR: albumin/globulin ratio
*: p value ≤ 0.05